NCT07834918Not yet recruiting
Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms
Clinical and Hematologic Risk Factors of Right Ventricular Dysfunction and Pulmonary Hypertension in Myeloproliferative Neoplasms
Source: ClinicalTrials.gov · Last updated 22 Sept 2026
Brief summary (registry, in English)
This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 145 (estimated)
- First submitted
- 17 Sept 2026
- Start date
- 20 Sept 2026
- Primary completion date
- 20 Sept 2027
- Lead sponsor
- Assiut University
- NCT number
- NCT07834918
What you commit to
- Study type: Observational
- Planned participants: 145
- From 20 Sept 2026 to the primary completion date, 20 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Significant left-sided valvular heart disease
- Congenital heart disease
- COPD or interstitial lung disease causing pulmonary hypertension
Other
- Poor echocardiographic window
Who the study is looking for
- \- Age 18 years or older
- Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, or primary myelofibrosis)
- Stable clinical condition
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.